PCSK9 Inhibitors (Alirocumab, Evolocumab)
7,951 views
Cardiovascular Pharm (Old)
- Adenosine
- Magnesium
- Nitroprusside
- Nitrates
- Ivabradine
- Digoxin/Digitalis
- Class IA Antiarrhythmics
- Class IB Antiarrhythmics
- Class IC Antiarrhythmics
- Class II Antiarrhythmics
- Class III Antiarrhythmics - Amiodarone
- Class III Antiarrythmics - Sotalol
- Class III Antiarrhythmics - Ibutilide, Dofetilide
- Class IV Antiarrhythmics - Verapamil, Diltiazem
- HMG-CoA Reductase Inhibitors (Statins)
- Ezetimibe
- Fibrates
- PCSK9 Inhibitors (Alirocumab, Evolocumab)
- Fish Oil and Omega-3s
- Milrinone
- Aliskiren
- Hydralazine
- Ranolazine
- Sacubitril
Summary
Alirocumab and evolocumab are PCSK9 inhibitors, a class of cholesterol-lowering drugs. They act by inhibiting PCSK9, a protease that binds and breaks down LDL receptors. This results in an increase in LDL receptor levels in the liver, which increases liver uptake of LDL and decreases LDL levels in the blood. This decrease in circulating LDL is what makes these drugs useful in the treatment of hypercholesterolemia.